Skip to main content
SRPT
NASDAQ Life Sciences

Stockholders Approve New Equity Incentive and Employee Stock Purchase Plans

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$16.74
Mkt Cap
$1.759B
52W Low
$10.415
52W High
$43.916
52W Position info
61% above low
Off High info
62% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SRPT sits 61% above its 52-week low of $10.415.

Summary

Sarepta Therapeutics' stockholders approved new equity incentive and employee stock purchase plans, authorizing the future issuance of up to 7.79 million shares, representing a potential dilution of approximately 7.38%.


Key Events · Financing and Capital Events · SRPT

  • Equity Incentive Plan Approved

    Stockholders approved the 2026 Equity Incentive Plan, authorizing the future issuance of up to 6,286,841 shares of common stock for employee and director awards.

  • Employee Stock Purchase Plan Approved

    Stockholders approved the 2026 Employee Stock Purchase Plan, making an additional 1,500,000 shares available for employee purchases.

  • Director Elections

    Five Class I director nominees were elected to the Board for a two-year term.

  • Executive Compensation Approved

    Stockholders provided advisory approval for the compensation of named executive officers for 2025.


Analysis · SRPT · Life Sciences

Sarepta Therapeutics' stockholders approved two new equity plans, authorizing the future issuance of up to 7,786,841 shares. This represents a potential dilution of approximately 7.38% to existing shareholders if all authorized shares are issued. These plans are crucial for attracting and retaining talent through stock-based compensation and employee stock purchases, which is a standard practice for growth companies in the life sciences sector.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRPT was trading at $16.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $10.42 to $43.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRPT - Latest Insights

SRPT
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.93
Real-time Price: $13.60 info
Change: -$4.33 (-24%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.65
Real-time Price: $13.60 info
Change: -$3.05 (-18%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.57
Real-time Price: $13.60 info
Change: -$3.97 (-23%) info
Market Cap: $1.429B info
SRPT
Sep 30, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $13.60 info
Change: -$5.04 (-27%) info
Market Cap: $1.429B info
SRPT
Sep 23, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.03
Real-time Price: $13.60 info
Change: -$5.43 (-29%) info
Market Cap: $1.429B info